{"url_path":"/sec/bmrn/8-k/2026-06-04/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/1048477/0001628280-26-040812-index.html","accession_number":"0001628280-26-040812","cik":"0001048477","ticker":"BMRN","issuer_name":"BIOMARIN PHARMACEUTICAL INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1048477/0001628280-26-040812-index.html","primary_entity_key":"0001048477","primary_entity_name":"BIOMARIN PHARMACEUTICAL INC"},"word_count":419,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nA total of 193,270,028 shares of common stock were entitled to vote as of April 7, 2026, the record date for the Annual Meeting. There were 175,813,292 shares of common stock present in person or represented by proxy at the Annual Meeting at which the stockholders were asked to vote on four proposals, each of which is described in more detail in the Proxy Statement. Set forth below are the matters acted upon by the stockholders, and the final voting results of each such proposal.\n\nProposal 1: Election of Directors\n\nDirectors ElectedForAgainstAbstainBroker Non-Votes\n\nElizabeth M. Anderson152,826,85511,325,40041,99511,619,042\n\nBarbara W. Bodem162,832,241796,989565,02011,619,042\n\nIan T. Clark144,380,10119,160,530653,61911,619,042\n\nAthena Countouriotis162,326,0651,823,39944,78611,619,042\n\nWillard Dere161,112,6062,973,541108,10311,619,042\n\nMark J. Enyedy161,113,3253,032,04048,88511,619,042\n\nAlexander Hardy163,115,6331,028,50650,11111,619,042\n\nMaykin Ho160,849,4373,300,11744,69611,619,042\n\nRobert J. Hombach160,262,5013,342,524589,22511,619,042\n\nTimothy P. Walbert158,544,6835,554,11695,45111,619,042\n\nBased on the votes set forth above, BioMarin’s stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner, until the director’s death, resignation or removal.\n\nProposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm\n\nThe ratification of the selection of KPMG LLP as BioMarin’s independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth in the Proxy Statement, received the following votes:\n\nForAgainstAbstain\n\n170,867,3354,850,52695,431\n\nBased on the votes set forth above, BioMarin’s stockholders ratified the selection of KPMG LLP as BioMarin’s independent registered public accounting firm to serve for the year ending December 31, 2026.\n\nProposal 3: Advisory Vote on the Compensation of Named Executive Officers\n\nThe advisory (non-binding) vote to approve the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement, received the following votes:\n\nForAgainstAbstainBroker Non-Votes\n\n142,742,80021,287,767163,68311,619,042\n\nBased on the votes set forth above, BioMarin’s stockholders approved, on an advisory basis, the compensation of BioMarin’s named executive officers, as set forth in the Proxy Statement.\n\nProposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan\n\nThe approval of the Plan Amendment received the following votes:\n\nForAgainstAbstainBroker Non-Votes\n\n158,561,8675,480,380152,00311,619,042\n\nBased on the votes set forth above, BioMarin’s stockholders approved the Plan Amendment.\n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nBioMarin Pharmaceutical Inc.,\na Delaware corporation\n\nDate: June 4, 2026By:/s/ G. Eric Davis\n\nG. Eric Davis\n\nExecutive Vice President, Chief Legal Officer"}